At the news
? NEUTRALIMPACT 3/10 8-K filed Jun 5, 2026 at 16:10 ET
Lifecore Biomedical filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the 2026 Stock Incentive Plan and elected nine directors. The new plan authorizes 2.5 million new shares plus any forfeited shares from the prior 2019 plan, becoming effective October 16, 2026. This is a routine governance filing with no material financial impact.
- Stockholders approved the 2026 Stock Incentive Plan with 22,724,492 votes for, 392,825 against, and 13,086 abstentions.
- The 2026 Plan authorizes 2,500,000 new shares plus any forfeited shares from the 2019 Plan.
- The 2026 Plan becomes effective October 16, 2026, replacing the 2019 Stock Incentive Plan.
- All nine director nominees were elected, including two Series A Preferred directors elected solely by preferred stockholders.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access